{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T20:48:36Z","timestamp":1782074916513,"version":"3.54.5"},"reference-count":70,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Autoimmune (AI) comorbidities are common in people with multiple sclerosis (MS) and may complicate therapeutic management, particularly when dual immunosuppression is required. Cladribine, an immune reconstitution therapy approved for relapsing MS, has shown potential benefit in selected autoimmune disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the prevalence of AI comorbidities in a large French MS cohort and explore the potential efficacy of cladribine in MS patients with concomitant autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective multicenter registry analysis combined with a descriptive case series and literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>Data were retrospectively extracted from the European Database for MS across five French tertiary MS centers. Adults with MS and documented autoimmune comorbidities were identified, including a subgroup treated with oral cladribine. In addition, eight detailed clinical cases of MS associated with autoimmune diseases treated with cladribine were reviewed to assess outcomes on both MS and the associated autoimmune condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 11,410 people with MS, 901 had at least one autoimmune comorbidity, corresponding to a prevalence of 7.9\u2009\u00b1\u20090.25% (age 50.8\u2009years), with a predominance of women. Of 385 cladribine-treated patients, 39 (10.1%\u2009\u00b1\u20091.54%) had concurrent autoimmune disorders, although this proportion did not significantly differ from the overall cohort (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.11). Eight cases involving ankylosing spondylitis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093), psoriatic arthritis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20092), psoriasis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091), rheumatoid arthritis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091), and sarcoidosis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091) were analyzed. Cladribine was consistently associated with MS stability, while efficacy on associated autoimmune conditions was variable, with more favorable outcomes observed in ankylosing spondylitis, psoriasis, and sarcoidosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Autoimmune comorbidities affect approximately 8% of the French MS population and are more frequent in women. Cladribine may represent a useful therapeutic option in selected patients with concomitant autoimmune disorders, potentially limiting prolonged dual immunosuppression. Larger prospective studies are required to confirm efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>OFSEP\/EDMUS registry, ClinicalTrials.gov: NCT02889965.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864261458568","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:07:18Z","timestamp":1781777238000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-3548","authenticated-orcid":false,"given":"Vito A. G.","family":"Ricigliano","sequence":"first","affiliation":[{"name":"Neurology Unit, GHNE Paris-Saclay Hospital, 1 parvis de l\u2019Hopital, Orsay 91400, France"},{"name":"Universit\u00e9 Paris-Saclay, UNIACT, Neurospin \u2013 INSERM UMR 1129, CEA, Gif-sur-Yvette, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Masmoudi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amiens University Hospital, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pital Fondation Adolphe de Rothschild, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Manchon","sequence":"additional","affiliation":[{"name":"Department of Neurology, CH de Gonesse, Gonesse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"De Seze","sequence":"additional","affiliation":[{"name":"Department of Neurology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.33"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004716"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn408"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13351-2"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564490"},{"key":"e_1_3_4_8_2","first-page":"98","article-title":"The prevalence of autoimmune diseases in patients with multiple sclerosis: a cross-sectional study in Qom, Iran, in 2018","volume":"19","author":"Ershadinia N","year":"2020","unstructured":"Ershadinia N, Mortazavinia N, Babaniamansour S, et al. The prevalence of autoimmune diseases in patients with multiple sclerosis: a cross-sectional study in Qom, Iran, in 2018. Curr J Neurol 2020; 19: 98\u2013102.","journal-title":"Curr J Neurol"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105204"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103754"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00351-2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6790-1"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4086-2"},{"key":"e_1_3_4_14_2","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data","volume":"25","author":"Kaine J","year":"2019","unstructured":"Kaine J, Song X, Kim G, et al. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. Administrative claims data. J Manag Care Spec Pharm 2019; 25: 122\u2013132.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1996.tb00004.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003999"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514521515"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70135-6"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70019"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2920"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103312"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30067-3"},{"key":"e_1_3_4_23_2","article-title":"Cladribine: off-label disease modification for people with multiple sclerosis in resource-poor settings?","volume":"4","author":"Mao Z","year":"2018","unstructured":"Mao Z, \u00c1lvarez-Gonzalez C, De Trane S, et al. Cladribine: off-label disease modification for people with multiple sclerosis in resource-poor settings? Mult Scler J Exp Transl Clin 2018; 4: 2055217318783767.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.praneu.2025.01.011"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1162"},{"key":"e_1_3_4_26_2","volume-title":"ACTRIMS Forum 2026","author":"Leist T","unstructured":"Leist T, Yamout B, Alexandri N, et al. Safety of cladribine tablets in the treatment of people with multiple sclerosis: 2025 Post-approval safety update. Presented at ACTRIMS Forum 2026. San Diego, CA, February 5\u20137, 2026."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-026-13753-w"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106398"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00496-3"},{"key":"e_1_3_4_30_2","article-title":"European experience of cladribine tablets in elderly patients with multiple sclerosis: could it be the last treatment?","volume":"11","author":"de Seze J","year":"2025","unstructured":"de Seze J, Zecca C, Castelnovo G, et al. European experience of cladribine tablets in elderly patients with multiple sclerosis: could it be the last treatment? Mult Scler J Exp Transl Clin 2025; 11: 20552173251321810.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_31_2","article-title":"Cladribine: a useful treatment option in multiple sclerosis patients with autoimmune comorbidities","volume":"30","author":"Lu J","year":"2025","unstructured":"Lu J, Brownlee WJ. Cladribine: a useful treatment option in multiple sclerosis patients with autoimmune comorbidities. Mult Scler 2025; 30: 13524585251396293.","journal-title":"Mult Scler"},{"key":"e_1_3_4_32_2","article-title":"Cladribine monotherapy in a patient with coexisting Crohn\u2019s disease and multiple sclerosis","volume":"30","author":"Dauby S","year":"2025","unstructured":"Dauby S, Dive D, Hansen I, et al. Cladribine monotherapy in a patient with coexisting Crohn\u2019s disease and multiple sclerosis. Mult Scler 2025 30: 13524585251390859.","journal-title":"Mult Scler"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208706"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_3_4_37_2","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl II): ii14\u2013ii17.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381112"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059223"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70373-7"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-002-0554-4"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S511351"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38954.689583.DE"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000992"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217802"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320113"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000792"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019174"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036491"},{"key":"e_1_3_4_52_2","first-page":"1287","article-title":"Secukinumab in RRMS: randomized proof-of-concept","volume":"263","author":"Havrdov\u00e1 E","year":"2016","unstructured":"Havrdov\u00e1 E, Belova A, Goloborodko A, et al. Secukinumab in RRMS: randomized proof-of-concept. J Neurol 2016; 263: 1287\u20131295.","journal-title":"J Neurol"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70173-X"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70023"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature01661"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(21)00467-1"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009749709065702"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4828"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114865"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-025-00414-y"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00452.x"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-017-0100-y"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01037-3"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac665"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.4414\/SMW.2022.w30049"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0025-9"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12793"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc032345"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2015.05.032"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261458568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261458568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261458568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T20:18:29Z","timestamp":1782073109000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261458568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"alternative-id":["10.1177\/17562864261458568"],"URL":"https:\/\/doi.org\/10.1177\/17562864261458568","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17562864261458568"}}